Vivos Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Vivos Therapeutics, Inc. announced its fiscal year 2025 results, showing a 16% increase in total revenue to $17.4 million, driven by growth in sleep testing services and treatment revenue, despite a decline in product sales.
NASDAQ
Vivos Therapeutics pivots towards strategic alliances and acquisitions to drive revenue growth after mixed results in 2024.
NASDAQ
10-K/A: Vivos Therapeutics Amends 2023 Annual Report Due to Typographical Error, Reaffirms Financials
Vivos Therapeutics has filed an amendment to its 2023 annual report to correct a minor typographical error, while reaffirming the accuracy of its financial statements.
NASDAQ
10-K: Vivos Therapeutics Reports Full Year 2023 Results, Navigates Market Challenges and Strategic Shifts
Vivos Therapeutics reports a net loss of $13.6 million for 2023, while implementing strategic changes and navigating market headwinds.